meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 1st line (L1)
11
mRCC - L1 - PDL1 negative
1
mRCC - L1 - PDL1 positive
4
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
avelumab based treatment
avelumab plus axitinib
nivolumab based treatment
nivolumab plus cabozantinib
pembrolizumab based treatment
pembrolizumab plus axitinib
pembrolizumab plus lenvatinib
Immune checkpoint association
nivolumab plus ipilimumab
mTOR inhibitors
everolimus
lenvatinib plus everolimus
VEGF(R) inhibitor
lenvatinib
lenvatinib in association